Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic natural killer cells IDP-023

A preparation of off-the-shelf (OTS) allogeneic, natural killer (NK) cells that contains g minus NK cells (G-NKs), with potential cytolytic and antineoplastic activities. Upon administration, allogeneic NK cells IDP-023 recognize and lyse cancer cells. These cells also secrete pro-inflammatory cytokines, which further stimulate an anti-tumor immune response. G-NKs are deficient in the FceR1g protein and show increased cytokine secretion, higher levels of cytolytic enzymes, increased persistence, and higher antibody dependent cell mediated cytotoxicity (ADCC) when combined with monoclonal antibody treatment.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic NK cells IDP-023
allogeneic NKs IDP-023
Code name:IDP 023
IDP-023
IDP023
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search